Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

NCT03949231 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: PD1/PDL1 inhibitor

Sponsor

Second Affiliated Hospital of Guangzhou Medical University